UNAIDS calls for urgent analysis and more research on hormonal contraceptives and HIV infection risk

6 October 2011

The Joint United Nations Programme on HIV/AIDS (UNAIDS) is following with concern data from recent studies suggesting that women using hormonal contraceptives are at increased risk of acquiring HIV infection from their partners and transmitting HIV to them. The benefits of quality hormonal contraception have been repeatedly demonstrated and must be considered while evaluating the potential for increased risk of HIV infection.

All women should have access to safe family planning methods to meet their sexual and reproductive health needs. Access to safe contraception is also vital to reducing maternal and infant mortality and contributes to decreasing new HIV infections in children.

There have been a number of studies on the impact that hormonal contraceptives may have on the risk of HIV infection. Some have shown increased risk while others have shown no significant increase in risk of HIV infection. The studies must be further analyzed to guide policy decisions and to determine the programmatic implications.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical